GTx execs' sole drug fails the lead indication study in a painful setback -- shares smashed
GTx’s $GTXI big catalyst has blown up in their faces.
The Memphis-based biotech says that their Phase II ASTRID study comparing two doses of enobosarm …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
